When.com Web Search

  1. Ads

    related to: novo nordisk patient education diabetes

Search results

  1. Results From The WOW.Com Content Network
  2. US FDA approves Novo Nordisk's Ozempic to cut risk of ... - AOL

    www.aol.com/news/us-fda-approves-novo-nordisks...

    Novo's blockbuster diabetes drug Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same active ingredient as its popular obesity treatment Wegovy. The U.S. Food and ...

  3. NNC2215 - Wikipedia

    en.wikipedia.org/wiki/NNC2215

    The drug is designed by a team of Novo Nordisk researchers. [1] NNC2215 can sense the glucose concentration presence in blood. The protein's sensitivity is reduced when low concentration of glucose, thus reducing the risk of hypoglycemia. [2] In addition, it can effectively cover the risk of fluctuations of blood sugar levels.

  4. Novo Nordisk's Ozempic slows diabetic kidney disease ... - AOL

    www.aol.com/news/novo-nordisks-ozempic-slows...

    Novo Nordisk's Ozempic slowed the worsening of kidney dysfunction in patients with type 2 diabetes and lowered the risk of kidney failure, heart problems, stroke and death, according to detailed ...

  5. Novo kidney trial finds Ozempic cuts cardiac deaths in diabetics

    www.aol.com/news/novo-kidney-trial-finds-ozempic...

    Novo Nordisk's widely used diabetes drug Ozempic delayed progression of chronic kidney disease in diabetes patients, a large late-stage study found, cutting the risk of death from that and major ...

  6. US FDA panel votes against Novo Nordisk's weekly insulin in ...

    www.aol.com/news/us-fda-panel-votes-against...

    Novo is aiming to be the first to hit the market with a weekly insulin product, offering an alternative for patients with type 1 and type 2 diabetes who now depend on multiple daily injections. "I ...

  7. Novo Nordisk - Wikipedia

    en.wikipedia.org/wiki/Novo_Nordisk

    Novo Nordisk works with doctors, nurses, and patients, to develop products for self-managing diabetes conditions. The DAWN (Diabetes Attitudes, Wishes and Needs) 2001 study was a global survey of the psychosocial aspects of living with diabetes.

  1. Ad

    related to: novo nordisk patient education diabetes